南华生物医药股份有限公司关于债权转让暨关联交易的进展公告

Group 1 - The company has approved the transfer of accounts receivable to Hunan Caixin Asset Management Co., Ltd. for a value of 23.4144 million yuan, as part of its operational needs [1] - The full subsidiary, Nanhua Stem Cell Regenerative Medicine Clinical Transformation Research Center, has received the payment of 23.4144 million yuan from Caixin Asset, completing the debt transfer process [2] - The announcement includes reference documents such as the Debt Transfer Agreement and the Bank Electronic Receipt [3]